|
시장보고서
상품코드
1671092
세계의 중증근무력증 질환 시장 규모, 점유율, 동향, 업계 분석 : 치료 유형별, 최종 용도별, 지역별 - 예측(2025-2034년)Global Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Use, and Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 중증근무력증 질환 시장 규모는 2034년까지 61억 9,000만 달러에 달할 전망입니다. 현재 시장 역학에 대한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
중증 근무력증(MG)은 골격근, 특히 안근, 표정근, 사지 등 의지 운동을 조절하는 근육의 쇠약을 유발하는 만성 자가면역질환입니다. 이 질환은 신체의 면역체계가 신경세포와 근육세포 간의 의사소통을 방해하는 항체를 생성하여 신호의 정상적인 전달을 방해함으로써 발병합니다.
중증 근무력증 질환 시장은 세계 유병률 증가, 진단 기술 발전, 보다 효과적인 치료 옵션에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 단클론 항체 및 면역 요법과 같은 생물제제의 개발 및 승인으로 중증 중증 근무력증에 대처할 수 있는 새로운 방법이 환자들에게 제공되고 있습니다.
또한 유전자 및 분자 프로파일에 따라 치료법을 조정하는 맞춤형 의료 동향도 주목받고 있습니다. 중증 근무력증 질환 시장의 성장은 환자 인식 증가, 임상시험의 확대, 특히 아시아태평양과 같은 신흥 시장에서 의료 접근성 향상에 의해 지원되고 있습니다. 난치성 환자의 니즈에 대한 대응, 치료 비용의 경제성 개선, 첨단 치료에 대한 접근성 확대 등이 기회 요인으로 작용하고 있습니다. 전반적으로 보다 효과적이고 접근하기 쉬운 치료 옵션이 계속 등장함에 따라 시장은 꾸준히 성장할 것으로 보입니다.
중증 근무력증 질환 시장 : 분석 개요
중증 근무력증 시장은 콜린에스테라아제 억제제가 주류를 이루고 있으며, 대부분의 경증 및 중등도 환자들에게 주요 치료제로 작용하고 있습니다. 그러나 중증 환자의 고급 치료에 대한 수요가 증가함에 따라 IVIG와 혈장투여를 포함한 신속 면역요법 분야가 가장 빠른 성장세를 보이고 있습니다.
중증 근무력증 질환 시장에서 병원은 급성 악화부터 중증까지 종합적인 치료를 제공하므로 병원이 가장 큰 시장 점유율을 차지하고 있습니다. 그러나 외래 치료로의 전환과 전문적 치료에 대한 접근성 향상으로 인해 클리닉 부문이 가장 빠르게 성장하고 있습니다.
북미는 첨단화된 의료 인프라, 높은 인지도, 많은 환자 수로 인해 중증 근무력증 시장을 주도하고 있습니다. 그러나 아시아태평양은 의료 접근성 확대, 진단 능력 향상, 혁신적인 치료법 채택 증가로 인해 가장 빠르게 성장하는 시장으로 부상하고 있습니다.
목차
제1장 서론
제2장 개요
제3장 분석 방법
제4장 중증근무력증 질환 시장 인사이트
- 시장 스냅숏
- 중증근무력증 질환 시장 역학
- 촉진요인과 기회
- 표적치료에 대한 주목의 증가
- 면역치료의 진보
- 억제요인과 과제
- 낮은 생존률
- 촉진요인과 기회
- PESTLE 분석
- 중증근무력증 질환 시장 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 중증근무력증 질환 시장 : 치료 유형별
- 주요 조사 결과
- 서론
- 흉선 적출술
- 콜린에스테라아제 저해제
- 신속한 면역치료
제6장 세계의 중증근무력증 질환 시장 : 최종 용도별
- 주요 조사 결과
- 서론
- 과학 조사
- 의약품·백신 연구개발
- 클론 실험
- 기타
제7장 세계의 중증근무력증 질환 시장 : 지역별
- 주요 분석 결과
- 서론
- 중증근무력증 질환 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 치료 유형별(2020-2034년)
- 북미 : 최종 용도별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 치료 유형별(2020-2034년)
- 유럽 : 최종 용도별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 치료 유형별(2020-2034년)
- 아시아태평양 : 최종 용도별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 치료 유형별(2020-2034년)
- 중동 및 아프리카 : 최종 용도별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 치료 유형별(2020-2034년)
- 라틴아메리카 : 최종 용도별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제9장 기업 개요
- Alexion Pharmaceuticals(AstraZeneca)
- Mitsubishi Tanabe Pharma
- Bristol Myers Squibb
- Grifols
- Baxter International
- CSL Behring
- UCB
- Prothena Biosciences
- Argenx
- Sanofi
- Amgen
- AbbVie
- Pfizer
- Roche
- Novartis
The myasthenia gravis disease market size is expected to reach USD 6.19 billion by 2034, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Thymectomy, Cholinesterase Inhibitors, and Rapid Immunotherapies), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those responsible for controlling voluntary movements like eye muscles, facial muscles, and limbs. The condition occurs when the body's immune system produces antibodies that interfere with the communication between nerve cells and muscle cells, preventing the normal transmission of signals.
The myasthenia gravis disease market is driven by several factors, including the increasing global prevalence of the condition, advancements in diagnostic techniques, and the growing demand for more effective treatment options. The development and approval of biologic therapies, such as monoclonal antibodies and immunotherapies, are offering patients new ways to manage severe forms of the disease.
Additionally, the trend toward personalized medicine, which tailors treatments based on genetic and molecular profiles, is gaining traction. The myasthenia gravis disease market growth is also supported by rising patient awareness, the expansion of clinical trials, and improving healthcare access, particularly in emerging markets such as Asia Pacific. Opportunities lie in addressing the needs of refractory patients, improving treatment affordability, and expanding access to advanced therapies. Overall, the market is poised for steady growth as more effective and accessible treatment options continue to emerge.
Myasthenia Gravis Disease Market Report Highlights
Cholinesterase inhibitors dominate the myasthenia gravis market, serving as the primary treatment for most patients with mild to moderate symptoms. However, the segment of rapid immunotherapies, including IVIG and plasmapheresis, is registering the fastest growth due to increasing demand for advanced therapies in severe cases.
Hospitals hold the largest myasthenia gravis disease market share in the myasthenia gravis treatment market, as they provide comprehensive care for both acute exacerbations and severe MG cases. The clinic segment, however, is experiencing the fastest growth, driven by the increasing shift towards outpatient care and improved accessibility to specialized treatments.
North America dominates the myasthenia gravis market, owing to its advanced healthcare infrastructure, high awareness, and significant patient population. However, Asia Pacific is the fastest growing market, driven by expanding healthcare access, improving diagnostic capabilities, and increasing adoption of innovative therapies.
Polaris Market Research has segmented the myasthenia gravis disease market report based on treatment type, end-use, and region:
By Treatment Type Outlook (Revenue-USD Billion, 2020 - 2034)
- Thymectomy
- Cholinesterase Inhibitors
- Rapid Immunotherapies
By End Use Outlook (Revenue-USD Billion, 2020 - 2034)
- Hospitals
- Clinics
By Regional Outlook (Revenue-USD Billion, 2020 - 2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Myasthenia Gravis Disease Market Insights
- 4.1. Myasthenia Gravis Disease Market - Market Snapshot
- 4.2. Myasthenia Gravis Disease Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increased Focus on Targeted Therapies
- 4.2.1.2. Advancements in Immunotherapy
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Low Survival Rates
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Myasthenia Gravis Disease Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Myasthenia Gravis Disease Market, by Treatment Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 5.3. Thymectomy
- 5.3.1. Global Myasthenia Gravis Disease Market, by Thymectomy, by Region, 2020-2034 (USD Billion)
- 5.4. Cholinesterase Inhibitors
- 5.4.1. Global Myasthenia Gravis Disease Market, by Cholinesterase Inhibitors, by Region, 2020-2034 (USD Billion)
- 5.5. Rapid Immunotherapies
- 5.5.1. Global Myasthenia Gravis Disease Market, by Rapid Immunotherapies, by Region, 2020-2034 (USD Billion)
6. Global Myasthenia Gravis Disease Market, by End-use
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 6.3. Scientific Research
- 6.3.1. Global Myasthenia Gravis Disease Market, by Scientific Research, by Region, 2020-2034 (USD Billion)
- 6.4. Medicine and Vaccine R&D
- 6.4.1. Global Myasthenia Gravis Disease Market, by Medicine and Vaccine R&D, by Region, 2020-2034 (USD Billion)
- 6.5. Cloning Experiment
- 6.5.1. Global Myasthenia Gravis Disease Market, by Cloning Experiment, by Region, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. Global Myasthenia Gravis Disease Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Myasthenia Gravis Disease Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Myasthenia Gravis Disease Market Assessment, By Geography, 2020-2034 (USD Billion)
- 7.3. Myasthenia Gravis Disease Market - North America
- 7.3.1. North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.3.2. North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.3.3. Myasthenia Gravis Disease Market - U.S.
- 7.3.3.1. U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.3.3.2. U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.3.4. Myasthenia Gravis Disease Market - Canada
- 7.3.4.1. Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.3.4.2. Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4. Myasthenia Gravis Disease Market - Europe
- 7.4.1. Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.2. Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.3. Myasthenia Gravis Disease Market - UK
- 7.4.3.1. UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.3.2. UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.4. Myasthenia Gravis Disease Market - France
- 7.4.4.1. France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.4.2. France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.5. Myasthenia Gravis Disease Market - Germany
- 7.4.5.1. Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.5.2. Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.6. Myasthenia Gravis Disease Market - Italy
- 7.4.6.1. Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.6.2. Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.7. Myasthenia Gravis Disease Market - Spain
- 7.4.7.1. Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.7.2. Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.8. Myasthenia Gravis Disease Market - Netherlands
- 7.4.8.1. Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.8.2. Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.9. Myasthenia Gravis Disease Market - Russia
- 7.4.9.1. Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.9.2. Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.4.10. Myasthenia Gravis Disease Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.4.10.2. Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5. Myasthenia Gravis Disease Market - Asia Pacific
- 7.5.1. Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.2. Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.3. Myasthenia Gravis Disease Market - China
- 7.5.3.1. China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.3.2. China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.4. Myasthenia Gravis Disease Market - India
- 7.5.4.1. India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.4.2. India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.5. Myasthenia Gravis Disease Market - Malaysia
- 7.5.5.1. Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.5.2. Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.6. Myasthenia Gravis Disease Market - Japan
- 7.5.6.1. Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.6.2. Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.7. Myasthenia Gravis Disease Market - Indonesia
- 7.5.7.1. Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.7.2. Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.8. Myasthenia Gravis Disease Market - South Korea
- 7.5.8.1. South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.8.2. South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.9. Myasthenia Gravis Disease Market - Australia
- 7.5.9.1. Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.9.2. Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.5.10. Myasthenia Gravis Disease Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.5.10.2. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6. Myasthenia Gravis Disease Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.2. Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.3. Myasthenia Gravis Disease Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.3.2. Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.4. Myasthenia Gravis Disease Market - UAE
- 7.6.4.1. UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.4.2. UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.5. Myasthenia Gravis Disease Market - Israel
- 7.6.5.1. Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.5.2. Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.6. Myasthenia Gravis Disease Market - South Africa
- 7.6.6.1. South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.6.2. South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.6.7. Myasthenia Gravis Disease Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.6.7.2. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7. Myasthenia Gravis Disease Market - Latin America
- 7.7.1. Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.7.2. Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.3. Myasthenia Gravis Disease Market - Mexico
- 7.7.3.1. Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.7.3.2. Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.4. Myasthenia Gravis Disease Market - Brazil
- 7.7.4.1. Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.7.4.2. Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.5. Myasthenia Gravis Disease Market - Argentina
- 7.7.5.1. Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.7.5.2. Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
- 7.7.6. Myasthenia Gravis Disease Market - Rest of Latin America
- 7.7.6.1. Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
- 7.7.6.2. Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Alexion Pharmaceuticals (AstraZeneca)
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Mitsubishi Tanabe Pharma
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Bristol Myers Squibb
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Grifols
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Baxter International
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. CSL Behring
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. UCB
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Prothena Biosciences
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Argenx
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Sanofi
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Amgen
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. AbbVie
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Pfizer
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. Roche
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. Novartis
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
